Skip to main content

Table 3. Clinical Activity Associated with Atezolizumab Monotherapy in the Phase 1 PCD48989g Study

From: Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge 2018” (28–29 November, 2018, Naples, Italy)

Back to article page